Author

B. Lavginova

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Predictors of suboptimal peak inspiratory flow in patients with COPD exacerbation

Incorrect inhalation technique is one of the main causes of ineffective inhaled therapy in patients with chronic obstructive pulmonary disease (COPD), leading to increased frequency of exacerbations and hospitalizations. Measuring peak inspiratory flow (PIF) and determining its optimal values for a specific dry powder...

N. Trushenko, B. Lavginova, G. N. Nekludova et al. · PULMONOLOGIYA · 0 citations

Review Open access Oct 2026

Triple combination ivacaftor + tezacaftor + elexacaftor and ivacaftor for cystic fibrosis: clinical efficacy and safety of the original drug and its generic analogue Trilexa®

Triple CFTR modulator therapy with ivacaftor + tezacaftor + elexacaftor and ivacaftor (ITE) has substantially changed the clinical course and prognosis of cystic fibrosis. The expanding use of the bioequivalent generic Trilexa® highlights the need to summarize evidence on its clinical efficacy and safety, including out...

Z. Merzhoeva, I. Levina, B. Lavginova et al. · PULMONOLOGIYA · 0 citations

Open access Aug 2026

Triple CFTR modulator therapy in severe cystic fibrosis-associated liver disease: a case report of an adverse outcome and the role of adherence to follow-up

Background. Cystic fibrosis (CF) is a multisystem disease in which liver involvement occurs in 20-40% of patients. The introduction of CFTR modulator therapy has substantially improved the prognosis of patients with CF; however, patients with established cirrhosis have typically been excluded from clinical trials, whic...

Z. Merzhoeva, O. Suvorova, I. A. Levina et al. · Lechaschi Vrach · 0 citations